PL424452A1 - Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu - Google Patents

Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu

Info

Publication number
PL424452A1
PL424452A1 PL424452A PL42445218A PL424452A1 PL 424452 A1 PL424452 A1 PL 424452A1 PL 424452 A PL424452 A PL 424452A PL 42445218 A PL42445218 A PL 42445218A PL 424452 A1 PL424452 A1 PL 424452A1
Authority
PL
Poland
Prior art keywords
endopeptidase
hsep
nep
prevention
treatment
Prior art date
Application number
PL424452A
Other languages
English (en)
Inventor
Christopher Turski
Original Assignee
Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością filed Critical Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL424452A priority Critical patent/PL424452A1/pl
Priority to RS20240670A priority patent/RS65651B1/sr
Priority to US16/963,234 priority patent/US20210046097A1/en
Priority to IL275984A priority patent/IL275984B2/en
Priority to PCT/PL2019/000012 priority patent/WO2019151882A1/en
Priority to ES19747023T priority patent/ES2983982T3/es
Priority to PL19747023.0T priority patent/PL3746106T3/pl
Priority to HRP20240728TT priority patent/HRP20240728T1/hr
Priority to RU2020125048A priority patent/RU2758771C1/ru
Priority to TW108103768A priority patent/TWI762760B/zh
Priority to KR1020207025030A priority patent/KR102867067B1/ko
Priority to CN201980011177.2A priority patent/CN111757750A/zh
Priority to CA3088966A priority patent/CA3088966C/en
Priority to EP19747023.0A priority patent/EP3746106B1/en
Priority to MX2020007989A priority patent/MX2020007989A/es
Priority to HUE19747023A priority patent/HUE067550T2/hu
Priority to CN202411008786.1A priority patent/CN118948867A/zh
Publication of PL424452A1 publication Critical patent/PL424452A1/pl
Priority to ZA2019/05959A priority patent/ZA201905959B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Zgłoszenie dotyczy nowego zastosowania pochodnych benzazepiny, benzoksazepiny, kwasu benzotiazepino-N-octowego oraz fosfono-podstawionego benzazepinonu o aktywności hamującej obojętną endopeptydazę (NEP) i/lub ludzką rozpuszczalną endopeptydazę (hSEP). Związki te stosuje się do wytwarzania kompozycji farmaceutycznych do profilaktyki i leczenia chorób oczu.
PL424452A 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu PL424452A1 (pl)

Priority Applications (18)

Application Number Priority Date Filing Date Title
PL424452A PL424452A1 (pl) 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
TW108103768A TWI762760B (zh) 2018-01-31 2019-01-31 用於預防或治療眼部疾病的中性肽鏈內切酶(NEP)及人類可溶性肽鏈內切酶(hSEP)之抑制劑
KR1020207025030A KR102867067B1 (ko) 2018-01-31 2019-01-31 안 질환의 예방 및 치료를 위한 중성 엔도펩티다제 (NEP) 및 사람 용해성 엔도펩티다제 (hSEP) 억제제
IL275984A IL275984B2 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs
PCT/PL2019/000012 WO2019151882A1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases
ES19747023T ES2983982T3 (es) 2018-01-31 2019-01-31 Inhibidores de endopeptidasa neutra (NEP) y endopeptidasa soluble humana (HSEP) para la profilaxis y el tratamiento de enfermedades oftalmológicas
PL19747023.0T PL3746106T3 (pl) 2018-01-31 2019-01-31 Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu
HRP20240728TT HRP20240728T1 (hr) 2018-01-31 2019-01-31 Inhibitori neutralne endopeptidaze (nep) i humane topljive endopeptidaze (hsep) za profilaksu i liječenje bolesti oka
RU2020125048A RU2758771C1 (ru) 2018-01-31 2019-01-31 ИНГИБИТОРЫ НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ (НЭП) И РАСТВОРИМОЙ ЭНДОПЕПТИДАЗЫ ЧЕЛОВЕКА (РЭПч) ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГЛАЗНЫХ БОЛЕЗНЕЙ
RS20240670A RS65651B1 (sr) 2018-01-31 2019-01-31 Inhibitori neutralne endopeptidaze (nep) i humane rastvorive endopeptidaze (hsep) za profilaksu i lečenje očnih bolesti
US16/963,234 US20210046097A1 (en) 2018-01-31 2019-01-31 NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES
CN201980011177.2A CN111757750A (zh) 2018-01-31 2019-01-31 用于预防和治疗眼病的中性内肽酶(nep)及人类可溶性内肽酶(hsep)的抑制剂
CA3088966A CA3088966C (en) 2018-01-31 2019-01-31 Neutral Endopeptidase (NE) and Soluble Human Endopeptidase Inhibitors for the Prevention and Treatment of Eye Diseases
EP19747023.0A EP3746106B1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases
MX2020007989A MX2020007989A (es) 2018-01-31 2019-01-31 Inhibidores de endopeptidasa neutra (nep) y endopeptidasa soluble humana (hsep) para profilaxis y tratamiento de enfermedades oftalmologicas.
HUE19747023A HUE067550T2 (hu) 2018-01-31 2019-01-31 Neutrális endopeptidáz (NEP) és humán oldható endopeptidáz (HSEP) gátlószerek szembetegségek megelõzésére és kezelésére
CN202411008786.1A CN118948867A (zh) 2018-01-31 2019-01-31 用于预防和治疗眼病的中性内肽酶(nep)及人类可溶性内肽酶(hsep)的抑制剂
ZA2019/05959A ZA201905959B (en) 2018-01-31 2019-09-10 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL424452A PL424452A1 (pl) 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu

Publications (1)

Publication Number Publication Date
PL424452A1 true PL424452A1 (pl) 2019-08-12

Family

ID=67478423

Family Applications (2)

Application Number Title Priority Date Filing Date
PL424452A PL424452A1 (pl) 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
PL19747023.0T PL3746106T3 (pl) 2018-01-31 2019-01-31 Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19747023.0T PL3746106T3 (pl) 2018-01-31 2019-01-31 Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu

Country Status (16)

Country Link
US (1) US20210046097A1 (pl)
EP (1) EP3746106B1 (pl)
KR (1) KR102867067B1 (pl)
CN (2) CN118948867A (pl)
CA (1) CA3088966C (pl)
ES (1) ES2983982T3 (pl)
HR (1) HRP20240728T1 (pl)
HU (1) HUE067550T2 (pl)
IL (1) IL275984B2 (pl)
MX (1) MX2020007989A (pl)
PL (2) PL424452A1 (pl)
RS (1) RS65651B1 (pl)
RU (1) RU2758771C1 (pl)
TW (1) TWI762760B (pl)
WO (1) WO2019151882A1 (pl)
ZA (1) ZA201905959B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL424453A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
KR102647920B1 (ko) 2021-10-13 2024-03-13 영남대학교 산학협력단 거짓비늘 녹내장 바이오 마커
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191436B1 (pl) * 1997-11-12 2006-05-31 Solvay Pharm Gmbh Podstawione ugrupowaniem kwasu fosfonowego pochodne benzazepinonu zawierające przy atomie N-ugrupowanie kwasu octowego, sposób ich wytwarzania i środki farmaceutyczne zawierające te związki
EP1706121A1 (en) * 2004-01-12 2006-10-04 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
WO2007056497A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
KR20010041605A (ko) * 1998-03-05 2001-05-25 요시다 쇼지 안저 조직 세포병리와 관련된 질환의 예방 및 치료용 제약조성물
PL367093A1 (pl) * 2001-05-18 2005-02-21 Solvay Pharmaceuticals Gmbh Zastosowanie związków o łącznej aktywności inhibitorowej wobec NEP/MP do wytwarzania leków
KR100979077B1 (ko) * 2002-01-16 2010-08-31 솔베이 파마슈티칼스 비. 브이 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (en) 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
CL2004000545A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
KR101137084B1 (ko) * 2003-10-10 2012-04-24 애보트 프러덕츠 게엠베하 셀렉티브 ⅰ１ 이미다졸린 수용체 작용제 및 엔지오텐신 ⅱ수용체 차단제를 포함하는 약학적 조성물
US7232813B2 (en) * 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
EP4302829B1 (en) * 2009-08-24 2025-05-21 Stealth BioTherapeutics Inc. Peptide for use in preventing or treating macular degeneration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191436B1 (pl) * 1997-11-12 2006-05-31 Solvay Pharm Gmbh Podstawione ugrupowaniem kwasu fosfonowego pochodne benzazepinonu zawierające przy atomie N-ugrupowanie kwasu octowego, sposób ich wytwarzania i środki farmaceutyczne zawierające te związki
EP1706121A1 (en) * 2004-01-12 2006-10-04 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
WO2007056497A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators

Also Published As

Publication number Publication date
EP3746106B1 (en) 2024-03-27
WO2019151882A4 (en) 2019-09-26
TW201934536A (zh) 2019-09-01
ZA201905959B (en) 2021-07-28
MX2020007989A (es) 2020-09-09
CN111757750A (zh) 2020-10-09
RS65651B1 (sr) 2024-07-31
KR20200116145A (ko) 2020-10-08
CA3088966C (en) 2025-06-03
CA3088966A1 (en) 2019-08-08
EP3746106A1 (en) 2020-12-09
IL275984B2 (en) 2025-08-01
HRP20240728T1 (hr) 2024-08-30
CN118948867A (zh) 2024-11-15
WO2019151882A1 (en) 2019-08-08
HUE067550T2 (hu) 2024-10-28
PL3746106T3 (pl) 2024-06-24
EP3746106A4 (en) 2021-11-03
EP3746106C0 (en) 2024-03-27
TWI762760B (zh) 2022-05-01
US20210046097A1 (en) 2021-02-18
IL275984B1 (en) 2025-04-01
ES2983982T3 (es) 2024-10-28
IL275984A (en) 2020-08-31
RU2758771C1 (ru) 2021-11-01
KR102867067B1 (ko) 2025-10-01

Similar Documents

Publication Publication Date Title
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12021551302A1 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
CL2015003442A1 (es) Derivados heterociclicos
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
PH12013502090A1 (en) 1,3 oxazines as bace1 and/or bace2 inhibitors
PH12013502316A1 (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
PH12020551891A1 (en) New quinoline derivatives
PH12019502365A1 (en) New bicyclic pyrazole derivatives
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PL424452A1 (pl) Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
CO2017007691A2 (es) Inhibidores de la β-secretasa derivados de la 5-amino-3-(5-(3-isoxazol-5-il)-3-(fluorometil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina o 5-amino-3-(5-(1h-1,2,3-triazol-4-il)-2-fluorofenil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina composiciones que los comprenden y métodos de elaboración
WO2012102560A3 (ko) 신규한 4-ｏ-메틸호노키올 유도체 및 이를 유효성분으로 포함하는 염증질환 치료용 조성물
EP4371613A3 (en) Compounds for use in the treatment of ocular pain
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.